Vig­il Neu­ro­science launch­es with a $50M Se­ries A and two for­mer Am­gen neu­ro­science can­di­dates

Af­ter more than 20 years in the in­dus­try, Ivana Magov­če­vić-Liebisch had done it all — ex­cept build a com­pa­ny from scratch. Then Bruce Booth at At­las Ven­ture men­tioned a cou­ple of TREM2 as­sets he was try­ing to snag from Am­gen’s old neu­ro­science pipeline.

“I came in to help them bring the as­sets in,” Magov­če­vić-Liebisch said. “As we start­ed work­ing to­geth­er, it be­came a clear fit… It kind of checked all the box­es.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER